Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04139018 · ClinicalTrials.gov registry record · Phase 2
Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT04139018 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 27 participants.
The verdict
NCT04139018, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study is a double-blinded, randomized controlled trial to evaluate the efficacy of an intranasal topical timolol gel in the care for epistaxis in adults with hereditary hemorrhagic telangiectasia.
Interventions
- DRUG Placebo Gel
- DRUG Timolol Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2019-10-20 |
| Est. Completion | 2020-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04139018
The ClinicalTrials.gov registry entry for NCT04139018 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Gel is the first listed.
NCT04139018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04139018 about?
NCT04139018 is a clinical study titled "Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia". This study is a double-blinded, randomized controlled trial to evaluate the efficacy of an intranasal topical timolol gel in the care for epistaxis in adults with hereditary hemorrhagic telangiectasia.
What is the current status of trial NCT04139018?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2019-10-20. Estimated completion is 2020-05-20.
What interventions are being tested in trial NCT04139018?
The interventions under investigation include: Placebo Gel (DRUG), Timolol Gel (DRUG).
Who is sponsoring clinical trial NCT04139018?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.